{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,23]],"date-time":"2025-12-23T18:46:56Z","timestamp":1766515616299,"version":"3.37.3"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T00:00:00Z","timestamp":1500249600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Transl Oncol"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1007\/s12094-017-1699-x","type":"journal-article","created":{"date-parts":[[2017,7,17]],"date-time":"2017-07-17T11:35:42Z","timestamp":1500291342000},"page":"1531-1536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Platelet\u2013lymphocyte and neutrophil\u2013lymphocyte ratios are prognostic but not predictive of response to abiraterone acetate in metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4076-4078","authenticated-orcid":false,"given":"A. J.","family":"Lozano Mart\u00ednez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Moreno Cano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Escobar P\u00e1ramo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Salguero Aguilar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Gonzalez Billalabeitia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Garc\u00eda Fern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"De La Fuente Mu\u00f1oz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Romero Borque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Porras Mart\u00ednez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Lopez Soler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Cardenas C\u00e1novas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I.","family":"Ortega Mart\u00edn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,17]]},"reference":[{"issue":"10","key":"1699_CR1","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","volume":"13","author":"K Fizazi","year":"2012","unstructured":"Fizazi K, Scher HI, Molina A, et al. Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. Lancet Oncol. 2012;13(10):983\u201392.","journal-title":"Lancet Oncol"},{"issue":"2","key":"1699_CR2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","volume":"368","author":"CJ Ryan","year":"2013","unstructured":"Ryan CJ, Smith MR, de Bono JS, et al. Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med. 2013;368(2):138\u201348.","journal-title":"N Engl J Med"},{"issue":"5","key":"1699_CR3","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med. 2014;371(5):424\u201333.","journal-title":"N Engl J Med"},{"issue":"Suppl. 2","key":"1699_CR4","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0959-8049(11)70100-9","volume":"47","author":"C Parker","year":"2011","unstructured":"Parker C, Heinrich D, O\u2019Sullivan JM, et al. Overall survival benefit of radium-223 chloride (AlpharadinTM) in the treatment of patients with symptomatic bone metastases in Castration-resistant Prostate Cancer (CRPC): a phase III randomized trial (ALSYMPCA). Eur J Cancer. 2011;47(Suppl. 2):3.","journal-title":"Eur J Cancer"},{"issue":"9747","key":"1699_CR5","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","volume":"376","author":"JS Bono De","year":"2010","unstructured":"De Bono JS, Oudard S, Ozguroglu M, et al. Prednisone plus cabazitaxel or mitoxantrone for metastasis castration-resistant prostate cancer progressing after docetaxel treatment: a randomized open-label trial. Lancet. 2010;376(9747):1147\u201354.","journal-title":"Lancet"},{"issue":"1","key":"1699_CR6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1002\/cncr.23106","volume":"112","author":"MW Kattan","year":"2008","unstructured":"Kattan MW, Cuzick J, Fisher G, et al. Nomogram incorporating PSA level to predict cancer-specific survival for men with clinically localized prostate cancer managed without curative intent. Cancer. 2008;112(1):69\u201374.","journal-title":"Cancer"},{"issue":"7","key":"1699_CR7","doi-asserted-by":"crossref","first-page":"1232","DOI":"10.1200\/JCO.2003.06.100","volume":"21","author":"S Halabi","year":"2003","unstructured":"Halabi S, Small EJ, Kantoff PW, et al. Prognostic model for predicting survival in men with hormone-refractory metastatic prostate cancer. J Clin Oncol. 2003;21(7):1232\u20137.","journal-title":"J Clin Oncol"},{"key":"1699_CR8","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646\u201374.","journal-title":"Cell"},{"key":"1699_CR9","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.cell.2010.01.025","volume":"140","author":"SI Grivennikov","year":"2010","unstructured":"Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010;140:883\u201399.","journal-title":"Cell"},{"key":"1699_CR10","doi-asserted-by":"crossref","unstructured":"Ferro M, De Cobelli O, Buonerba C, et al. Modified Glasgow Prognostic Score is associated with risk of recurrence in bladder cancer after radical cystectomy: a multicenter experience D. Medicine (Baltimore). 2015;94(42):e1861.","DOI":"10.1097\/MD.0000000000001861"},{"issue":"6","key":"1699_CR11","doi-asserted-by":"crossref","first-page":"dju124","DOI":"10.1093\/jnci\/dju124","volume":"106","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, McNamara MG, Seruga B, et al. Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014;106(6):dju124.","journal-title":"J Natl Cancer Inst"},{"key":"1699_CR12","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/hdi.12040","volume":"17","author":"K Turkmen","year":"2013","unstructured":"Turkmen K, Erdur FM, Ozcicek F, Ozcicek A, Akbas EM, Ozbicer A, Demirtas L, Turk S, Tonbul HZ. Platelet-to-lymphocyte ratio better predicts inflammation than neutrophil-to-lymphocyte ratio in end-stage renal disease patients. Hemodial Int. 2013;17:391\u20136.","journal-title":"Hemodial Int"},{"issue":"21","key":"1699_CR13","doi-asserted-by":"crossref","first-page":"3346","DOI":"10.1002\/cncr.28890","volume":"120","author":"AJ Templeton","year":"2014","unstructured":"Templeton AJ, Pezaro C, Omlin A, et al. Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer. 2014;120(21):3346\u201352.","journal-title":"Cancer"},{"issue":"9","key":"1699_CR14","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1111\/iju.12839","volume":"22","author":"A Yao","year":"2015","unstructured":"Yao A, Sejima T, Iwamoto H, et al. High neutrophil-to-lymphocyte ratio predicts poor clinical outcome in patients with castration-resistant prostate cancer treated with docetaxel chemotherapy. Int J Urol. 2015;22(9):827\u201333.","journal-title":"Int J Urol"},{"issue":"6b","key":"1699_CR15","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1111\/bju.12531","volume":"114","author":"P Nuhn","year":"2014","unstructured":"Nuhn P, Vaghasia AM, Goyal J, et al. Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel. Br J Urol Int. 2014;114(6b):E11\u20137.","journal-title":"Br J Urol Int"},{"issue":"7","key":"1699_CR16","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1093\/carcin\/bgp127","volume":"30","author":"F Colotta","year":"2009","unstructured":"Colotta F, Allavena P, Sica A, et al. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073\u201381.","journal-title":"Carcinogenesis"},{"issue":"1","key":"1699_CR17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.critrevonc.2013.03.010","volume":"88","author":"GJ Guthrie","year":"2013","unstructured":"Guthrie GJ, Charles KA, Roxburgh CS, et al. The systemic inflammation-based neutrophil\u2013lymphocyte ratio: experience in patients with cancer. Crit Rev Oncol Hematol. 2013;88(1):218\u201330.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"7","key":"1699_CR18","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1158\/0008-5472.CAN-10-2583","volume":"71","author":"AD Gregory","year":"2011","unstructured":"Gregory AD, Houghton AM. Tumor-associated neutrophils: new targets for cancer therapy. Cancer Res. 2011;71(7):2411\u20136.","journal-title":"Cancer Res"},{"issue":"3","key":"1699_CR19","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1093\/annonc\/mdt581","volume":"25","author":"R Leibowitz-Amit","year":"2014","unstructured":"Leibowitz-Amit R, Templeton AJ, Omlin A, et al. Clinical variables associated with PSA response to abiraterone acetate in patients with metastatic castration-resistant prostate cancer. Ann Oncol. 2014;25(3):657\u201362.","journal-title":"Ann Oncol"},{"issue":"8","key":"1699_CR20","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1007\/s11255-014-0664-7","volume":"46","author":"AT Sumbul","year":"2014","unstructured":"Sumbul AT, Sezer A, Abali H, et al. Neutrophil-to-lymphocyte ratio predicts PSA response, but not outcomes in patients with castration-resistant prostate cancer treated with docetaxel. Int Urol Nephrol. 2014;46(8):1531\u20135.","journal-title":"Int Urol Nephrol"},{"issue":"suppl","key":"1699_CR21","doi-asserted-by":"crossref","first-page":"abstr 4553","DOI":"10.1200\/jco.2012.30.15_suppl.4553","volume":"30","author":"D Bianchini","year":"2012","unstructured":"Bianchini D, Kaur Sandhu S, Mulick A, Zivi A, Mezynski J, Mukherji D, et al. Durable radiologic and clinical disease stability beyond PSA progression in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA). J Clin Oncol. 2012;30(suppl):abstr 4553.","journal-title":"J Clin Oncol"},{"issue":"10","key":"1699_CR22","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s12032-014-0239-6","volume":"31","author":"K Neofytou","year":"2014","unstructured":"Neofytou K, Smyth EC, Giakoustidis A, Khan AZ, Cunningham D, Mudan S. Elevated platelet to lymphocyte ratio predicts poor prognosis after hepatectomy for liver-only colorectal metastases, and it is superior to neutrophil to lymphocyte ratio as an adverse prognostic factor. Med Oncol. 2014;31(10):239.","journal-title":"Med Oncol"}],"container-title":["Clinical and Translational Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12094-017-1699-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1699-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12094-017-1699-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,12]],"date-time":"2020-10-12T18:03:33Z","timestamp":1602525813000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12094-017-1699-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,17]]},"references-count":22,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["1699"],"URL":"https:\/\/doi.org\/10.1007\/s12094-017-1699-x","relation":{},"ISSN":["1699-048X","1699-3055"],"issn-type":[{"type":"print","value":"1699-048X"},{"type":"electronic","value":"1699-3055"}],"subject":[],"published":{"date-parts":[[2017,7,17]]}}}